Bio-Rad Laboratories, Inc. (BIO) — Financial statements
Income statement, balance sheet, and cash flow for Bio-Rad Laboratories, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 2,583↑0.7% | 2,567↓3.9% | 2,671↓4.7% | 2,802↓4.1% | 2,923 | |
| Cost of Revenue | 1,240↑4.4% | 1,188↓4.6% | 1,244↑0.8% | 1,235↓3.9% | 1,284 | |
| Gross Profit | 1,344↓2.6% | 1,379↓3.4% | 1,427↓9.0% | 1,567↓4.3% | 1,638 | |
| Operating Expenses | ||||||
| R&D Expenses | 257↓13.2% | 296↑19.6% | 247↓3.7% | 257↓1.4% | 261 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 820↑0.7% | 814↓3.3% | 842↑1.7% | 828↓5.6% | 877 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 1,078↓2.9% | 1,110↑1.9% | 1,089↑0.4% | 1,085↓4.7% | 1,138 | |
| Total Costs & Expenses | 2,317↑0.9% | 2,298↓1.5% | 2,333↑0.6% | 2,320↓4.2% | 2,422 | |
| Operating Results | ||||||
| Operating Income | 271↑0.6% | 269↓20.4% | 338↓30.0% | 483↓3.5% | 500 | |
| Depreciation & Amortization | 205↑35.5% | 152↑3.9% | 146↓17.7% | 177↑28.8% | 138 | |
| EBITDA | 476↑122.2% | -2,142↓227.1% | -655↑85.4% | -4,489↓180.3% | 5,588 | |
| EBIT | 271↑111.8% | -2,294↓186.5% | -801↑82.8% | -4,666↓185.6% | 5,451 | |
| Interest & Other Income | ||||||
| Net Interest Income | 47↑40.5% | 33↓35.7% | 51↑158.8% | 20↑14.6% | 17 | |
| Interest Income | 96↑16.5% | 82↓18.7% | 101↑74.0% | 58↑206.9% | 19 | |
| Interest Expense | 49↑0.2% | 49↓1.1% | 49↑29.7% | 38↑2357.4% | 2 | |
| Non-Operating Income | 0.00↓100.0% | 2,563↑125.1% | 1,138↓77.9% | 5,149↑204.0% | -4,950 | |
| Other Income / Expenses | 725↑127.8% | -2,612↓119.8% | -1,188↑77.1% | -5,187↓204.8% | 4,949 | |
| Income Before Tax | 996↑142.5% | -2,343↓175.6% | -850↑81.9% | -4,704↓186.3% | 5,449 | |
| Income Tax Expense | 236↑147.3% | -498↓134.2% | -213↑80.2% | -1,077↓190.1% | 1,195 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 760↑141.2% | -1,844↓189.4% | -637↑82.4% | -3,628↓185.3% | 4,254 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 760↑141.2% | -1,844↓189.4% | -637↑82.4% | -3,628↓185.3% | 4,254 | |
| Bottom-Line Net Income | 760↑141.2% | -1,844↓189.4% | -637↑82.4% | -3,628↓185.3% | 4,254 | |
| EPS (Basic) | 27.87↑142.6% | -65.36↓199.5% | -21.82↑82.1% | -121.79↓185.4% | 142.61 | |
| EPS (Diluted) | 27.87↑142.6% | -65.36↓199.5% | -21.82↑82.1% | -121.79↓186.5% | 140.83 | |
| Weighted Average Shares | 27↓3.4% | 28↓3.4% | 29↓1.9% | 30↓0.2% | 30 | |
| Weighted Average Diluted Shares | 27↓3.3% | 28↓3.4% | 29↓1.9% | 30↓1.4% | 30 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.